What is the official website of Curium Türkiye ?

The official website of Curium Türkiye is http://www.monrol.com.

What is Curium Türkiye's cybersecurity risk score?

Curium Türkiye has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Curium Türkiye experienced?

According to Rankiteo, Curium Türkiye currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Curium Türkiye been affected by any supply chain cyber incidents ?

According to Rankiteo, Curium Türkiye has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Curium Türkiye have SOC 2 Type 1 certification ?

According to Rankiteo, Curium Türkiye is not certified under SOC 2 Type 1.

Does Curium Türkiye have SOC 2 Type 2 certification ?

According to Rankiteo, Curium Türkiye does not hold a SOC 2 Type 2 certification.

Does Curium Türkiye comply with GDPR ?

According to Rankiteo, Curium Türkiye is not listed as GDPR compliant.

Does Curium Türkiye have PCI DSS certification ?

According to Rankiteo, Curium Türkiye does not currently maintain PCI DSS compliance.

Does Curium Türkiye comply with HIPAA ?

According to Rankiteo, Curium Türkiye is not compliant with HIPAA regulations.

Does Curium Türkiye have ISO 27001 certification ?

According to Rankiteo,Curium Türkiye is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Curium Türkiye operate in ?

Curium Türkiye operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Curium Türkiye have ?

Curium Türkiye employs approximately 214 people worldwide.

Does Curium Türkiye own any subsidiaries ?

Curium Türkiye presently has no subsidiaries across any sectors.

How many LinkedIn followers does Curium Türkiye have ?

Curium Türkiye's official LinkedIn profile has approximately 18,700 followers.

What is the NAICS classification code for Curium Türkiye ?

Curium Türkiye is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Curium Türkiye have a Crunchbase profile ?

No, Curium Türkiye does not have a profile on Crunchbase.

Does Curium Türkiye have a LinkedIn profile ?

Yes, Curium Türkiye maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/curium-turkiye.

How many cybersecurity incidents has Curium Türkiye experienced ?

As of July 3, 2026, Rankiteo reports that Curium Türkiye has not experienced any cybersecurity incidents.

How many peer or competitor companies does Curium Türkiye have ?

Curium Türkiye has an estimated 5,700 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Curium Türkiye

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Curium Türkiye Vendor Cyber Rating & Cyber Score

monrol.com

Add Your Compliance Badge

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and

Curium Türkiye A.I CyberSecurity Scoring

Scoring History

Curium Türkiye

Curium Türkiye CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Curium Türkiye Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Curium Türkiye

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incident Types Curium Türkiye vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Curium Türkiye in 2026.

Incident History - Curium Türkiye (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Curium Türkiye Subsidiaries

Curium Türkiye

Pharmaceutical Manufacturing

Website: http://www.monrol.com

Company Size: 214

Eczacıbaşı TopluluğuManufacturing

Eczacıbaşı Yapı ÜrünleriWholesale Building Materials

VitrA KaroWholesale Building Materials

Eczacıbaşı İntemaWholesale Building Materials

Kanyon Yönetim İşletim ve Pazarlama A.Ş.Retail

EsanMining

Eczacıbaşı İlaç PazarlamaPharmaceutical Manufacturing

Loading…

Curium Türkiye Similar Companies

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Loading…

NEWS

Curium Türkiye CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57100

SUMMARY

Server-side request forgery (ssrf) in Microsoft Entra Provisioning Service (SyncFabric) allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.9)

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

3.1

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57100

CVE-2026-54998

SUMMARY

Incorrect authorization in Microsoft Exchange Online allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 8.8)

cvss3

Base Score: 8.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H

Impact Score

5.9

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-54998

CVE-2026-45499

SUMMARY

Server-side request forgery (ssrf) in Azure OpenAI allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.9)

cvss3

Base Score: 9.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H

Impact Score

Exploitability

3.1

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-45499

CVE-2026-41106

SUMMARY

Url redirection to untrusted site ('open redirect') in M365 Copilot allows an unauthorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 9.3)

cvss3

Base Score: 9.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:N

Impact Score

5.8

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-41106

CVE-2026-26145

SUMMARY

Improper access control in Azure Synapse allows an authorized attacker to elevate privileges over a network.

Published

Date2026-07-02

Updated

Date2026-07-02

RISK INFORMATION (Score: 4.8)

cvss3

Base Score: 4.8

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:R/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.2

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-26145

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…